Canagliflozin; Metformin Hydrochloride Patent Expiration
Canagliflozin; Metformin Hydrochloride is Used for reducing the risk of kidney disease, cardiovascular events, and treating type 2 diabetes mellitus patients. It was first introduced by Janssen Pharmaceuticals Inc
Canagliflozin; Metformin Hydrochloride Patents
Given below is the list of patents protecting Canagliflozin; Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Invokamet | US11576894 | Combination therapy for the treatment of diabetes | Jul 06, 2030 | Janssen Pharms |
| Invokamet | US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | Feb 26, 2029 | Janssen Pharms |
| Invokamet | US7943788 | Glucopyranoside compound | Jul 14, 2027 | Janssen Pharms |
| Invokamet | US8222219 | Glucopyranoside compound | Apr 11, 2025 | Janssen Pharms |
| Invokamet | US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | Dec 03, 2027 | Janssen Pharms |
| Invokamet | US8785403 | Glucopyranoside compound | Jul 30, 2024 | Janssen Pharms |
| Invokamet Xr | US6723340 | Optimal polymer mixtures for gastric retentive tablets |
Oct 25, 2021
(Expired) | Janssen Pharms |
| Invokamet Xr | US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | Feb 26, 2029 | Janssen Pharms |
| Invokamet Xr | US7943788 | Glucopyranoside compound | Jul 14, 2027 | Janssen Pharms |
| Invokamet Xr | US8222219 | Glucopyranoside compound | Apr 11, 2025 | Janssen Pharms |
| Invokamet Xr | US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | Dec 03, 2027 | Janssen Pharms |
| Invokamet Xr | US8785403 | Glucopyranoside compound | Jul 30, 2024 | Janssen Pharms |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳